These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 8368227)
1. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227 [TBL] [Abstract][Full Text] [Related]
2. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915 [TBL] [Abstract][Full Text] [Related]
3. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597 [TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Major PP; Coleman RE Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861 [TBL] [Abstract][Full Text] [Related]
5. Treatment of tumor-induced osteolysis by APD. Burckhardt P; Thiébaud D; Perey L; von Fliedner V Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665 [TBL] [Abstract][Full Text] [Related]
6. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Wimalawansa SJ Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530 [TBL] [Abstract][Full Text] [Related]
7. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Body JJ; Dumon JC Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034 [TBL] [Abstract][Full Text] [Related]
8. [Pamidronate in the treatment of tumor-associated hypercalcemia]. Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492 [TBL] [Abstract][Full Text] [Related]
9. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601 [TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662 [TBL] [Abstract][Full Text] [Related]
11. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. Body JJ; Borkowski A; Cleeren A; Bijvoet OL J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134 [TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851 [TBL] [Abstract][Full Text] [Related]
15. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089 [TBL] [Abstract][Full Text] [Related]
16. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198 [TBL] [Abstract][Full Text] [Related]
17. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184 [TBL] [Abstract][Full Text] [Related]
18. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Sekine M; Takami H Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321 [TBL] [Abstract][Full Text] [Related]
19. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Walls J; Ratcliffe WA; Howell A; Bundred NJ Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531 [TBL] [Abstract][Full Text] [Related]
20. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Gurney H; Kefford R; Stuart-Harris R Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]